TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34056067

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (details not available)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (details not available)
Number of subjects: 0
Study: 34046552

Group type: EXPERIMENTAL
Intervention: 12-week multidisciplinary rehabilitation programme
Number of subjects: 0
Study: 34056607

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa 1200 mg Q2W until disease progression, unacceptable toxicity, or trial withdrawal
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa 1200 mg Q2W
Number of subjects: 35
Study: 34056687

Group type: EXPERIMENTAL
Intervention: Treatment for advanced NSCLC (specific treatment details not available)
Number of subjects: 42
Study: 34056870

Group type: EXPERIMENTAL
Intervention: Surgical debridement, antibiotic, and hyperbaric oxygen therapy over a 6-month period
Number of subjects: 2

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 2
Study: 34056892

Group type: EXPERIMENTAL
Intervention: iVascular Luminor™ drug-coated balloon (DCB) and Angiolite™ drug-eluting stent
Number of subjects: 50
Study: 34056913

Group type: EXPERIMENTAL
Intervention: New-Onset Perioperative Atrial Fibrillation (POAF)
Number of subjects: 4624

Group type: COMPARATOR
Intervention: No New-Onset Perioperative Atrial Fibrillation (POAF)
Number of subjects: 4624
Study: 34057232

Group type: EXPERIMENTAL
Intervention: CAR-T (axicabtagene-ciloleucel; tisagenlecleucel)
Number of subjects: 0
Study: 34057424

Group type: EXPERIMENTAL
Intervention: Computer game-based rehabilitation program (GRP) for 16 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional therapy for 16 weeks
Number of subjects: 60
Study: 34057734

Group type: EXPERIMENTAL
Intervention: IPV training for healthcare providers (HCPs)
Number of subjects: 1662
Study: 34057820

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 346
Study: 34058027

Group type: EXPERIMENTAL
Intervention: Mirabegron (25 mg, increased to 50 mg if tolerated)
Number of subjects: 86
Study: 34058148

Group type: EXPERIMENTAL
Intervention: Increased MUC5AC concentrations
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: MUC5AC concentration
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: MUC5AC concentrations
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: MUC5AC
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: MUC5AC-producing pathways
Number of subjects: 331
Study: 34058856

Group type: EXPERIMENTAL
Intervention: Mean Arterial Pressure (MAP) measurement
Number of subjects: 0
Study: 34058888

Group type: EXPERIMENTAL
Intervention: 5% dextrose solution
Number of subjects: 17

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 17
Study: 34059026

Group type: EXPERIMENTAL
Intervention: Aldosterone to renin ratio (ARR) > 10 (ng/dL)/(mU/L) after confirmatory test
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Adrenal vein sampling (AVS)
Number of subjects: 141
Study: 34059046

Group type: EXPERIMENTAL
Intervention: Intraoperative hypothermia
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Age, bilateral procedure, ASA level, postoperative hypothermia
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Postoperative hypothermia
Number of subjects: 286
Study: 34059074

Group type: EXPERIMENTAL
Intervention: Technology-assisted, family volunteers delivered, parents' skills training intervention
Number of subjects: 540

Group type: COMPARATOR
Intervention: Enhanced treatment as usual (ETAU)
Number of subjects: 540
Study: 34059127

Group type: EXPERIMENTAL
Intervention: LDA model
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: RF model
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Dynamic Scheimpflug tonometry
Number of subjects: 434
Study: 34059148

Group type: EXPERIMENTAL
Intervention: Health Champions (trained volunteers providing support)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 120
Study: 34059276

Group type: EXPERIMENTAL
Intervention: Test strip (15% w/w calcium sodium phosphosilicate)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Test strip
Number of subjects: 120
Study: 34059384

Group type: EXPERIMENTAL
Intervention: Increased EAT attenuation (EAT-At), a marker of EAT inflammation
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: EAT volume
Number of subjects: 192
Study: 34059525

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 308

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 308

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 308
Study: 34059556

Group type: EXPERIMENTAL
Intervention: MRI imaging and muscle enzyme values (creatine phosphokinase and aldolase)
Number of subjects: 27
Study: 34059639

Group type: EXPERIMENTAL
Intervention: Fosciclopirox (CPX-POM) administered intraperitoneally at doses of 235 mg/kg and 470 mg/kg for four weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34059786

Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Plasma concentrations of leptin
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Plasma concentrations of adiponectin
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Leptin levels
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Adipokine levels
Number of subjects: 63
Study: 34059801

Group type: EXPERIMENTAL
Intervention: Defibrotide
Number of subjects: 104
Study: 34059991

Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide (TAF), median duration of dosing 74 weeks
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide (TAF)
Number of subjects: 500
Study: 34059995

Group type: EXPERIMENTAL
Intervention: Gastric bypass and fundoplication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34060012

Group type: EXPERIMENTAL
Intervention: NTK 120 mg once every 2 weeks (NTK Q2W)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: NTK 120 mg once every 4 weeks (NTK Q4W)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 34060434

Group type: EXPERIMENTAL
Intervention: Turkish version of the Aphasia Rapid Test (ART)
Number of subjects: 30
Study: 34060440

Group type: EXPERIMENTAL
Intervention: Ophthalmic grader pathway
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Ophthalmic grader pathway (seven-field Early Treatment Diabetic Retinopathy Study)
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Ophthalmic grader pathway (ultra-wide field imaging)
Number of subjects: 553
Study: 34060483

Group type: EXPERIMENTAL
Intervention: Systemic pharmacological blockade of activin A using soluble activin receptor type IIB ligand trap
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Muscle-specific adeno-associated virus-mediated downregulation of its receptor ACVR2A/B
Number of subjects: 0
Study: 34060704

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation discontinuation (≥7 consecutive days)
Number of subjects: 23882
Study: 34060705

Group type: EXPERIMENTAL
Intervention: Care Of the Dying Evaluation (i-CODE) questionnaire
Number of subjects: 914
Study: 34060714

Group type: EXPERIMENTAL
Intervention: Non-selective beta-blockers (NSBB) administered intravenously
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: MR elastography of the liver or spleen
Number of subjects: 52
Study: 34060926

Group type: EXPERIMENTAL
Intervention: Biofeedback-based approach to modify step length asymmetry in 15 individuals with marked asymmetry.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Walking without biofeedback.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Walking more symmetrically (post-biofeedback).
Number of subjects: 36
Study: 34061040

Group type: EXPERIMENTAL
Intervention: Dyadic physical activity intervention for 12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Delayed control condition
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dyadic physical activity intervention
Number of subjects: 20
Study: 34061122

Group type: EXPERIMENTAL
Intervention: Patient-directed educational intervention (video summarizing inpatient management guidelines)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 91
Study: 34061299

Group type: EXPERIMENTAL
Intervention: iMTA Productivity Cost Questionnaire (iPCQ)
Number of subjects: 144
Study: 34061352

Group type: COMPARATOR
Intervention: Suction aspiration after cervical preparation
Number of subjects: 17795

Group type: COMPARATOR
Intervention: Dilatation and curettage
Number of subjects: 17795

Group type: COMPARATOR
Intervention: Suction aspiration
Number of subjects: 17795

Group type: COMPARATOR
Intervention: Mifepristone plus misoprostol
Number of subjects: 17795

Group type: COMPARATOR
Intervention: Misoprostol
Number of subjects: 17795
Study: 34061581

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34061621

Group type: EXPERIMENTAL
Intervention: Hedonic hunger assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Binge eating assessment
Number of subjects: 0
Study: 34062314

Group type: EXPERIMENTAL
Intervention: Dilation performed 1 year or less before endoscopy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dilation performed more than 1 year before endoscopy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nondilated patients
Number of subjects: 100
Study: 34062626

Group type: EXPERIMENTAL
Intervention: Danish version of the Pain Self-Efficacy Questionnaire (PSEQ-DK)
Number of subjects: 92
Study: 34063194

Group type: EXPERIMENTAL
Intervention: Mindfulness (measured by the Five Facet Mindfulness Questionnaire)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Nonreactivity (a component of mindfulness)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Conscious presence and nonjudgment (components of mindfulness)
Number of subjects: 117
Study: 34064209

Group type: EXPERIMENTAL
Intervention: Chiropractic spinal adjustments combined with physical therapy (chiro + PT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Sham chiropractic with physical therapy (sham + PT)
Number of subjects: 63
Study: 34064657

Group type: EXPERIMENTAL
Intervention: Severe periodontitis
Number of subjects: 3271

Group type: COMPARATOR
Intervention: Participants without periodontitis or PAOD
Number of subjects: 3271
Study: 34065252

Group type: EXPERIMENTAL
Intervention: High HDL-C levels
Number of subjects: 1689

Group type: EXPERIMENTAL
Intervention: Socio-demographic and lifestyle factors
Number of subjects: 1689

Group type: EXPERIMENTAL
Intervention: Family history of cancer
Number of subjects: 1689
Study: 34065517

Group type: EXPERIMENTAL
Intervention: Integrative Psychotherapeutic Group Treatment (IPGT)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Self-Help Groups (SHG)
Number of subjects: 159
Study: 34065523

Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation program (12 weeks supervised by family caregivers)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual postoperative rehabilitation (control group)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation program
Number of subjects: 62
Study: 34065642

Group type: EXPERIMENTAL
Intervention: Contrast-associated acute kidney injury (CA-AKI)
Number of subjects: 870

Group type: COMPARATOR
Intervention: No contrast-associated acute kidney injury (No CA-AKI)
Number of subjects: 870
Study: 34065859

Group type: EXPERIMENTAL
Intervention: Venetoclax/S63845 combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NOXA expression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MCL-1 BH3 mimetic, S63845
Number of subjects: 0
Study: 34066300

Group type: EXPERIMENTAL
Intervention: Bifluorid 10
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Futurabond U
Number of subjects: 340
Study: 34066473

Group type: EXPERIMENTAL
Intervention: Mother's own milk (MOM)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Donor human milk (DHM)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Formula
Number of subjects: 117
Study: 34066713

Group type: EXPERIMENTAL
Intervention: CD34 Stem Cell Therapy
Number of subjects: 3000000

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 3000000
Study: 34066948

Group type: EXPERIMENTAL
Intervention: Profile 1: Low transactional sex and high power
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Profile 2: Moderate transactional sex and moderate power
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Profile 3: High transactional sex and low power
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Profile 4: Very high transactional sex and very low power
Number of subjects: 322
Study: 34067039

Group type: EXPERIMENTAL
Intervention: Corticosteroid continuation (CSC)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Corticosteroid withdrawal
Number of subjects: 105
Study: 34067093

Group type: EXPERIMENTAL
Intervention: Uncoupling protein 1 (UCP1), specific dosage and duration not mentioned
Number of subjects: 0
Study: 34068534

Group type: EXPERIMENTAL
Intervention: Structured home-based exercise (SHB) program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Walking advice (Control)
Number of subjects: 60
Study: 34069594

Group type: EXPERIMENTAL
Intervention: Milan criteria period (MilanCP)
Number of subjects: 523

Group type: COMPARATOR
Intervention: AFP model period (AFPscP)
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: AFP model
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Graft allocation policy
Number of subjects: 523
Study: 34070044

Group type: EXPERIMENTAL
Intervention: Daratumumab combined with Durvalumab
Number of subjects: 18
Study: 34070172

Group type: EXPERIMENTAL
Intervention: Azacytidine (AZA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fludarabine plus low-dose cytarabine (FLUGA)
Number of subjects: 0
Study: 34070561

Group type: EXPERIMENTAL
Intervention: Oxaliplatin (starting dose 100 mg/sm, maximum 300 mg/sm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin (starting dose 15 mg/sm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doxorubicin (starting dose 3 mg/sm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PIPAC (Pressurized Intra-Peritoneal Aerosol Chemotherapy)
Number of subjects: 0
Study: 34071188

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs) as first-line therapy for HCC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor (CAR)-engineered NK cells and T cells
Number of subjects: 0
Study: 34071908

Group type: EXPERIMENTAL
Intervention: Opioid maintenance therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34071967

Group type: EXPERIMENTAL
Intervention: Samsung Health application
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ECG M-Trace Base II application
Number of subjects: 0
Study: 34072165

Group type: EXPERIMENTAL
Intervention: Genetic predisposition to Alzheimer's Disease (AD)
Number of subjects: 680
Study: 34073782

Group type: EXPERIMENTAL
Intervention: Urinary Incontinence (UI) prevalence in female athletes
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Long-distance running
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Age and years of sport practice
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Absorbent pads usage
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Impact on sporting life
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Risk factors for UI
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Urinary tract infections or candidiasis
Number of subjects: 63
Study: 34074313

Group type: EXPERIMENTAL
Intervention: COVID-19 ARDS
Number of subjects: 120
Study: 34074827

Group type: EXPERIMENTAL
Intervention: Sedation
Number of subjects: 432202

Group type: COMPARATOR
Intervention: No Sedation
Number of subjects: 432202
Study: 34074856

Group type: COMPARATOR
Intervention: HBO2 (Hyperbaric Oxygen Therapy) within 6 hours
Number of subjects: 706
Study: 34074889

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (e.g., dapagliflozin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CREDENCE trial (control group with DKD)
Number of subjects: 0
Study: 34075392

Group type: EXPERIMENTAL
Intervention: AHEI score at 16-22 weeks
Number of subjects: 1887

Group type: EXPERIMENTAL
Intervention: DASH score at 8-13 weeks
Number of subjects: 1887

Group type: EXPERIMENTAL
Intervention: DASH score at 16-22 weeks
Number of subjects: 1887

Group type: EXPERIMENTAL
Intervention: AHEI score at 24-29 weeks
Number of subjects: 1887

Group type: EXPERIMENTAL
Intervention: AMED score at 8-13 weeks
Number of subjects: 1887

Group type: EXPERIMENTAL
Intervention: DASH score at 24-29 weeks
Number of subjects: 1887
Study: 34076556

Group type: EXPERIMENTAL
Intervention: MenB vaccine
Number of subjects: 0
Study: 34076745

Group type: EXPERIMENTAL
Intervention: Fluorine-18-labeled IL-2 PET imaging
Number of subjects: 0
Study: 34076831

Group type: EXPERIMENTAL
Intervention: Continuation group (tandem high-dose chemotherapy (HDCT) and craniospinal irradiation (CSI))
Number of subjects: 49

Group type: COMPARATOR
Intervention: Switched group (modified treatment)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Stable disease (SD) group
Number of subjects: 49

Group type: COMPARATOR
Intervention: Progressive disease (PD) group
Number of subjects: 49
Study: 34077628

Group type: EXPERIMENTAL
Intervention: Transient elastography (TE)
Number of subjects: 11440
Study: 34077678

Group type: EXPERIMENTAL
Intervention: Scoring of the lymphatic architecture and transport through near-infrared fluorescence lymphatic imaging
Number of subjects: 0
Study: 34078022

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg for 24 weeks, increased to 40 mg if necessary after 12 weeks
Number of subjects: 62
Study: 34078106

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy in patients with ASPECTS of 0 to 5
Number of subjects: 763

Group type: COMPARATOR
Intervention: Mechanical thrombectomy in patients with ASPECTS of 6 to 10
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Patients <65 years of age with ASPECTS 0-5
Number of subjects: 763
Study: 34078203

Group type: EXPERIMENTAL
Intervention: Primary Care-based delivery model with direct access to a diabetes educator
Number of subjects: 4894

Group type: COMPARATOR
Intervention: Usual care with referrals to traditional hospital-based outpatient DSMES programs
Number of subjects: 4894
Study: 34078234

Group type: EXPERIMENTAL
Intervention: Presence of interferon-λ 4 (IFN-λ4)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Male gender, absent/mild steatosis, low viral load
Number of subjects: 279
Study: 34078259

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA treatment
Number of subjects: 641
Study: 34078260

Group type: EXPERIMENTAL
Intervention: D-chiro-inositol (1 g/day) for 1 month
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 10
Study: 34078306

Group type: EXPERIMENTAL
Intervention: Family psychoeducation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basic family involvement and support scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family psychoeducation fidelity assessment scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General organizational index scale
Number of subjects: 0
Study: 34078399

Group type: EXPERIMENTAL
Intervention: Point of care ultrasound screening for DVT performed by ICU residents
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Point of care ultrasound screening for DVT
Number of subjects: 90

Group type: COMPARATOR
Intervention: Patients with VTE (n=8)
Number of subjects: 90
Study: 34078435

Group type: EXPERIMENTAL
Intervention: S100B > 0.10 μg/L
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: S100B < 0.10 μg/L
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: GFAP
Number of subjects: 566
Study: 34078477

Group type: EXPERIMENTAL
Intervention: Cuneiform nucleus deep brain stimulation (CnF DBS)
Number of subjects: 4
Study: 34078485

Group type: EXPERIMENTAL
Intervention: Childhood trauma severity as measured by the Childhood Trauma Questionnaire
Number of subjects: 554

Group type: COMPARATOR
Intervention: Healthy individuals without a psychiatric history
Number of subjects: 554
Study: 34078581

Group type: EXPERIMENTAL
Intervention: SAPIEN 3 THV in bicuspid AS
Number of subjects: 107

Group type: COMPARATOR
Intervention: SAPIEN 3 THV in tricuspid AS
Number of subjects: 107
Study: 34078652

Group type: EXPERIMENTAL
Intervention: Vorasidenib
Number of subjects: 93
Study: 34078651

Group type: EXPERIMENTAL
Intervention: FP-1305 (bexmarilimab), a humanized IgG4 anti-Clever-1 antibody
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study: 34078915

Group type: EXPERIMENTAL
Intervention: V160 vaccine
Number of subjects: 6
Study: 34079458

Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Number of subjects: 0
Study: 34079488

Group type: EXPERIMENTAL
Intervention: Flexibly-Dosed Intensive Cognitive Behavioral Therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34080074

Group type: EXPERIMENTAL
Intervention: Individualized PEEP optimization using electrical impedance tomography (EIT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard ventilation according to ARDS Network recommendations
Number of subjects: 20
Study: 34080123

Group type: EXPERIMENTAL
Intervention: Oral semaglutide (fed arm)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Oral semaglutide (fasting arm)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Oral semaglutide (reference arm)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Oral semaglutide (dosing conditions trial)
Number of subjects: 239
Study: 34080309

Group type: EXPERIMENTAL
Intervention: Milademetan with strong CYP3A inhibitor (itraconazole or posaconazole)
Number of subjects: 0
Study: 34080441

Group type: EXPERIMENTAL
Intervention: Acupuncture administered twice per week for 5 weeks, 30 min per session.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acupuncture protocol acceptability questionnaire.
Number of subjects: 6
Study: 34080708

Group type: EXPERIMENTAL
Intervention: Imipenem administered by a 4-h infusion of 1 g q6h
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 50

Group type: COMPARATOR
Intervention: ECMO support
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High dosage of imipenem
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dosage regimens in patients with renal impairment
Number of subjects: 50